Takeda Culls Shunned Ex-Shire Asset After EC Lifts Antimonopoly Concerns
But Data, Samples Made Available
Japanese firm says it will end SHP647 development after trying unsuccessfully to find takers for GI drug similar to its blockbuster Entyvio, first flagged by European authorities over competition worries.
You may also be interested in...
Japan’s largest pharma company says it has seen no impact on its financial results so far from the coronavirus pandemic, with continuing growth for mainstay drugs, and raises its profit forecasts for the fiscal year on favorable one-off factors.
Although oncology remained strong, Japanese major says it saw multiple impacts from the pandemic, including on hospital visits and clinical trial recruitment, and has already cut its full-year guidance.
Also, Osmotica licenses rights to ophthalmic drug in Japan, China and the EMEA nations to Santen; Lilly and Chi-Med revise their partnership around colorectal cancer drug Elunate.